Search

Your search keyword '"Adema, Gosse J."' showing total 965 results
Start Over Author "Adema, Gosse J."
965 results on '"Adema, Gosse J."'

4. An Atlas of Human Glycosylation Pathways Enables Display of the Human Glycome by Gene Engineered Cells

Author

Narimatsu, Yoshiki, Joshi, Hiren J, Nason, Rebecca, Van Coillie, Julie, Karlsson, Richard, Sun, Lingbo, Ye, Zilu, Chen, Yen-Hsi, Schjoldager, Katrine T, Steentoft, Catharina, Furukawa, Sanae, Bensing, Barbara A, Sullam, Paul M, Thompson, Andrew J, Paulson, James C, Büll, Christian, Adema, Gosse J, Mandel, Ulla, Hansen, Lars, Bennett, Eric Paul, Varki, Ajit, Vakhrushev, Sergey Y, Yang, Zhang, and Clausen, Henrik

Subjects
Biochemistry and Cell Biology, Biological Sciences, Biotechnology, Genetics, Human Genome, Emerging Infectious Diseases, Epitopes, Genetic Engineering, Glycosylation, Glycosyltransferases, HEK293 Cells, Humans, Metabolic Networks and Pathways, Oligosaccharides, Polysaccharides, Proteins, adhesin, carbohydrate, galectin, glycan array, glycoengineering, glycosylation, glycosyltransferase, lectin, microarray, siglec, Medical and Health Sciences, Developmental Biology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

The structural diversity of glycans on cells-the glycome-is vast and complex to decipher. Glycan arrays display oligosaccharides and are used to report glycan hapten binding epitopes. Glycan arrays are limited resources and present saccharides without the context of other glycans and glycoconjugates. We used maps of glycosylation pathways to generate a library of isogenic HEK293 cells with combinatorially engineered glycosylation capacities designed to display and dissect the genetic, biosynthetic, and structural basis for glycan binding in a natural context. The cell-based glycan array is self-renewable and reports glycosyltransferase genes required (or blocking) for interactions through logical sequential biosynthetic steps, which is predictive of structural glycan features involved and provides instructions for synthesis, recombinant production, and genetic dissection strategies. Broad utility of the cell-based glycan array is demonstrated, and we uncover higher order binding of microbial adhesins to clustered patches of O-glycans organized by their presentation on proteins.

Published
2019

6. Probing the binding specificities of human Siglecs by cell-based glycan arrays

Author

Büll, Christian, Nason, Rebecca, Sun, Lingbo, Van Coillie, Julie, Sørensen, Daniel Madriz, Moons, Sam J., Yang, Zhang, Arbitman, Steven, Fernandes, Steve M., Furukawa, Sanae, McBride, Ryan, Nycholat, Corwin M., Adema, Gosse J., Paulson, James C., Schnaar, Ronald L., Boltje, Thomas J., Clausen, Henrik, and Narimatsu, Yoshiki

Published
2021

7. The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases.

Author

Reste, Mariana, Ajazi, Kristi, Sayi-Yazgan, Ayca, Jankovic, Radmila, Bufan, Biljana, Brandau, Sven, Bækkevold, Espen S., Petitprez, Florent, Lindstedt, Malin, Adema, Gosse J., and Almeida, Catarina R.

Subjects
TERTIARY structure, DENDRITIC cells, B cells, IMMUNE response, T cells, AUTOIMMUNE diseases
Abstract

Tertiary Lymphoid Structures (TLS) are organized aggregates of immune cells such as T cells, B cells, and Dendritic Cells (DCs), as well as fibroblasts, formed postnatally in response to signals from cytokines and chemokines. Central to the function of TLS are DCs, professional antigen-presenting cells (APCs) that coordinate the adaptive immune response, and which can be classified into different subsets, with specific functions, and markers. In this article, we review current data on the contribution of different DC subsets to TLS function in cancer and autoimmunity, two opposite sides of the immune response. Different DC subsets can be found in different tumor types, correlating with cancer prognosis. Moreover, DCs are also present in TLS found in autoimmune and inflammatory conditions, contributing to disease development. Broadly, the presence of DCs in TLS appears to be associated with favorable clinical outcomes in cancer while in autoimmune pathologies these cells are associated with unfavorable prognosis. Therefore, it is important to analyze the complex functions of DCs within TLS in order to enhance our fundamental understanding of immune regulation but also as a possible route to create innovative clinical interventions designed for the specific needs of patients with diverse pathological diseases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma

Author

Rabold, Katrin, Zoodsma, Martijn, Grondman, Inge, Kuijpers, Yunus, Bremmers, Manita, Jaeger, Martin, Zhang, Bowen, Hobo, Willemijn, Bonenkamp, Han J., de Wilt, Johannes H. W., Janssen, Marcel J. R., Cornelissen, Lenneke A. M., van Engen-van Grunsven, Ilse C. H., Mulder, Willem J. M., Smit, Jan W. A., Adema, Gosse J., Netea, Mihai G., Li, Yang, Xu, Cheng-Jian, and Netea-Maier, Romana T.

Published
2022
Full Text
View/download PDF

10. Siglec‐7 and Siglec‐9 expression in primary triple negative and oestrogen receptor positive breast cancer and in vitro signalling.

Author

van Houtum, Eline JH, Valk, Anne HC, Granado, Daniel, Lok, Jasper, van den Bogaard, Lune, Remkes, Naomi, van Eck van der Sluijs, Jesper, Span, Paul N, Cornelissen, Lenneke AM, and Adema, Gosse J

Subjects
TRIPLE-negative breast cancer, METASTATIC breast cancer, CANCER patients, MYELOID cells, BREAST cancer
Abstract

Objectives: PD‐1/PD‐L1 immune checkpoint blockade can be an effective treatment for advanced breast cancer patients. However, patients with oestrogen receptor positive (ER+) tumors often display only low lymphocyte infiltration, while a large part of triple negative (TN) breast tumors does not generate an effective immunotherapy response. Therefore, new treatment strategies have to be developed. Here, we investigate Siglec‐7 and Siglec‐9 as novel ITIM‐bearing inhibitory immune checkpoint receptors similar to PD‐1, but expressed on a broader range of immune cells. Methods: We assessed Siglec‐7 and Siglec‐9 (ligand) expression in TN and ER+ breast cancer tumors and their breast cancer cell line‐induced signalling. Results: We report that Siglec‐7 and Siglec‐9 are highly expressed in TN tumors, and to a low extent in ER+ tumors. Siglec‐7 was observed on myeloid cells, T cells, and NK cells and Siglec‐9 preferentially on myeloid cells. Expression of sialoglycans, including Siglec‐7 and Siglec‐9 ligands, was observed in both TN and ER+ breast cancer tissue sections. Expression levels of Siglec‐7 and Siglec‐9 ligands were higher on in vitro cultured TN cell lines than ER+ cell lines. Importantly, by applying chimeric Siglec‐7 reporter cells, we showed the induction of Siglec‐7 signalling by multiple TN cell lines, but only by one ER+ cell line. Moreover, Siglec‐7 signalling is directly related to Siglec‐7 ligand expression levels of breast cancer cell lines. Conclusion: These data imply that immunotherapy targeting Siglec receptors may be particularly interesting for TN breast cancer patients not responding to current treatment strategies with tumors displaying high immune cell infiltration. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Glioma-Associated Sialoglycans Drive the Immune Suppressive Phenotype and Function of Myeloid Cells.

Author

Cornelissen, Lenneke A. M., Santegoets, Kim C. M., Kers-Rebel, Esther D., Bossmann, Sandra A. J. F. H., Ter Laan, Mark, Granado, Daniel, and Adema, Gosse J.

Subjects
MYELOID-derived suppressor cells, MYELOID cells, TREATMENT effectiveness, GLIOBLASTOMA multiforme, SIALIC acids
Abstract

The tumor microenvironment of glioblastoma IDH-wildtype is highly immune suppressive and is characterized by a strong component of myeloid-derived suppressor cells (MDSCs). To interfere with the immune suppressive functions of MDSCs, a comprehensive understanding on how MDSCs acquire their suppressive phenotype is essential. Previously, we and others have shown a distinct Sialic acid-binding immunoglobulin-like lectin (Siglec) receptor expression profile for MDSCs in glioblastoma. Siglec receptors can transmit inhibitory signals comparable to PD-1 and are suggested to act as glyco-immune checkpoints. Here, we investigated how glioma specific Siglec-sialic acid interactions influence myeloid immune suppressive functions. Co-culturing monocytes with glioblastoma cells induced CD163 expression on the monocytes. Upon desialylation of the glioblastoma cells, this induction of CD163 was hampered, and furthermore, the monocytes were now able to secrete higher amounts of IL-6 and TNFα compared to fully sialylated glioblastoma cells. Additionally, Siglec-specific triggering using anti-Siglec-7 or Siglec-9 antibodies displayed a decreased TNFα secretion by the monocytes, validating the role of the Siglec–Sialic axis in the co-culture experiments. Together, our results demonstrate that glioblastoma cells induce a myeloid immune-suppressive phenotype that could be partly rescued by lowering the glioblastoma-associated sialic acid levels. This manuscript supports further research of the Siglec–Sialic acid axis in the context of glioblastoma and its potential to improve clinical outcome. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Tumor glucose metabolism and the T cell glycocalyx: implication for T cell function.

Author

Schuurmans, Fabian, Wagemans, Kyra E., Adema, Gosse J., and Cornelissen, Lenneke A. M.

Subjects
T cells, CELL physiology, CELL metabolism, GLUCOSE metabolism, POST-translational modification
Abstract

The T cell is an immune cell subset highly effective in eliminating cancer cells. Cancer immunotherapy empowers T cells and occupies a solid position in cancer treatment. The response rate, however, remains relatively low (<30%). The efficacy of immunotherapy is highly dependent on T cell infiltration into the tumor microenvironment (TME) and the ability of these infiltrated T cells to sustain their function within the TME. A better understanding of the inhibitory impact of the TME on T cells is crucial to improve cancer immunotherapy. Tumor cells are well described for their switch into aerobic glycolysis (Warburg effect), resulting in high glucose consumption and a metabolically distinct TME. Conversely, glycosylation, a predominant posttranslational modification of proteins, also relies on glucose molecules. Proper glycosylation of T cell receptors influences the immunological synapse between T cells and tumor cells, thereby affecting T cell effector functions including their cytolytic and cytostatic activities. This review delves into the complex interplay between tumor glucose metabolism and the glycocalyx of T cells, shedding light on how the TME can induce alterations in the T cell glycocalyx, which can subsequently influence the T cell's ability to target and eliminate tumor cells. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Interactions among myeloid regulatory cells in cancer

Author

Umansky, Viktor, Adema, Gosse J., Baran, Jaroslaw, Brandau, Sven, Van Ginderachter, Jo A., Hu, Xiaoying, Jablonska, Jadwiga, Mojsilovic, Slavko, Papadaki, Helen A., Pico de Coaña, Yago, Santegoets, Kim C. M., Santibanez, Juan F., Serre, Karine, Si, Yu, Sieminska, Isabela, Velegraki, Maria, and Fridlender, Zvi G.

Published
2019
Full Text
View/download PDF

25. Saponin-based adjuvants enhance antigen cross-presentation in human CD11c+CD1c+CD5−CD163+conventional type 2 dendritic cells

Author

Ho, Nataschja I, primary, Huis in 't Veld, Lisa G M, additional, van Eck van der Sluijs, Jesper, additional, Heuts, Branco M H, additional, Looman, Maaike W G, additional, Kers-Rebel, Esther D, additional, van den Dries, Koen, additional, Dolstra, Harry, additional, Martens, Joost H A, additional, Hobo, Willemijn, additional, and Adema, Gosse J, additional

Published
2023
Full Text
View/download PDF

32. Supplementary Table 1 from Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients

Author

Lesterhuis, W. Joost, primary, de Vries, I. Jolanda M., primary, Schreibelt, Gerty, primary, Lambeck, Annechien J.A., primary, Aarntzen, Erik H.J.G., primary, Jacobs, Joannes F.M., primary, Scharenborg, Nicole M., primary, van de Rakt, Mandy W.M.M., primary, de Boer, Annemiek J., primary, Croockewit, Sandra, primary, van Rossum, Michelle M., primary, Mus, Roel, primary, Oyen, Wim J.G., primary, Boerman, Otto C., primary, Lucas, Sophie, primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 2 from Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

Author

Aarntzen, Erik H. J. G., primary, Schreibelt, Gerty, primary, Bol, Kalijn, primary, Lesterhuis, W. Joost, primary, Croockewit, Alexandra J., primary, de Wilt, Johannes H. W., primary, van Rossum, Michelle M., primary, Blokx, Willeke A. M., primary, Jacobs, Joannes F. M., primary, Duiveman-de Boer, Tjitske, primary, Schuurhuis, Danita H., primary, Mus, Roel, primary, Thielemans, Kris, primary, de Vries, I. Jolanda M., primary, Figdor, Carl G., primary, Punt, Cornelis J. A., primary, and Adema, Gosse J., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Data from Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents

Author

de Vries, I. Jolanda M., primary, Castelli, Chiara, primary, Huygens, Caroline, primary, Jacobs, Joannes F.M., primary, Stockis, Julie, primary, Schuler-Thurner, Beatrice, primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, Rivoltini, Licia, primary, Schuler, Gerold, primary, Coulie, Pierre G., primary, and Lucas, Sophie, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 3 from Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

Author

Aarntzen, Erik H. J. G., primary, Schreibelt, Gerty, primary, Bol, Kalijn, primary, Lesterhuis, W. Joost, primary, Croockewit, Alexandra J., primary, de Wilt, Johannes H. W., primary, van Rossum, Michelle M., primary, Blokx, Willeke A. M., primary, Jacobs, Joannes F. M., primary, Duiveman-de Boer, Tjitske, primary, Schuurhuis, Danita H., primary, Mus, Roel, primary, Thielemans, Kris, primary, de Vries, I. Jolanda M., primary, Figdor, Carl G., primary, Punt, Cornelis J. A., primary, and Adema, Gosse J., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 2 from Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients

Author

Lesterhuis, W. Joost, primary, de Vries, I. Jolanda M., primary, Schreibelt, Gerty, primary, Lambeck, Annechien J.A., primary, Aarntzen, Erik H.J.G., primary, Jacobs, Joannes F.M., primary, Scharenborg, Nicole M., primary, van de Rakt, Mandy W.M.M., primary, de Boer, Annemiek J., primary, Croockewit, Sandra, primary, van Rossum, Michelle M., primary, Mus, Roel, primary, Oyen, Wim J.G., primary, Boerman, Otto C., primary, Lucas, Sophie, primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table 1 from Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells

Author

Aarntzen, Erik H.J.G., primary, Srinivas, Mangala, primary, Bonetto, Fernando, primary, Cruz, Luis J., primary, Verdijk, Pauline, primary, Schreibelt, Gerty, primary, van de Rakt, Mandy, primary, Lesterhuis, W. Joost, primary, van Riel, Maichel, primary, Punt, Cornelius J.A., primary, Adema, Gosse J., primary, Heerschap, Arend, primary, Figdor, Carl G., primary, Oyen, Wim J., primary, and de Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 1 from Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients

Author

Lesterhuis, W. Joost, primary, de Vries, I. Jolanda M., primary, Schreibelt, Gerty, primary, Lambeck, Annechien J.A., primary, Aarntzen, Erik H.J.G., primary, Jacobs, Joannes F.M., primary, Scharenborg, Nicole M., primary, van de Rakt, Mandy W.M.M., primary, de Boer, Annemiek J., primary, Croockewit, Sandra, primary, van Rossum, Michelle M., primary, Mus, Roel, primary, Oyen, Wim J.G., primary, Boerman, Otto C., primary, Lucas, Sophie, primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 1 from Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

Author

Aarntzen, Erik H. J. G., primary, Schreibelt, Gerty, primary, Bol, Kalijn, primary, Lesterhuis, W. Joost, primary, Croockewit, Alexandra J., primary, de Wilt, Johannes H. W., primary, van Rossum, Michelle M., primary, Blokx, Willeke A. M., primary, Jacobs, Joannes F. M., primary, Duiveman-de Boer, Tjitske, primary, Schuurhuis, Danita H., primary, Mus, Roel, primary, Thielemans, Kris, primary, de Vries, I. Jolanda M., primary, Figdor, Carl G., primary, Punt, Cornelis J. A., primary, and Adema, Gosse J., primary

Published
2023
Full Text
View/download PDF

41. Figure S1-S13 from Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell–Mediated Tumor Immunity

Author

Büll, Christian, primary, Boltje, Thomas J., primary, Balneger, Natasja, primary, Weischer, Sarah M., primary, Wassink, Melissa, primary, van Gemst, Jasper J., primary, Bloemendal, Victor R., primary, Boon, Louis, primary, van der Vlag, Johan, primary, Heise, Torben, primary, den Brok, Martijn H., primary, and Adema, Gosse J., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 4 from Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma

Author

Aarntzen, Erik H.J.G., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Jacobs, Joannes F.M., primary, Lesterhuis, W. Joost, primary, Van Rossum, Michelle M., primary, Adema, Gosse J., primary, Figdor, Carl G., primary, Punt, Cornelis J.A., primary, and De Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table 1 from Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination

Author

Aarntzen, Erik H.J.G., primary, De Vries, I. Jolanda M., primary, Lesterhuis, W. Joost, primary, Schuurhuis, Danita, primary, Jacobs, Joannes F.M., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Mus, Roel, primary, De Wilt, Johannes H.W., primary, Haanen, John B.A.G., primary, Schadendorf, Dirk, primary, Croockewit, Alexandra, primary, Blokx, Willeke A.M., primary, Van Rossum, Michelle M., primary, Kwok, William W., primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 5 from Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma

Author

Aarntzen, Erik H.J.G., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Jacobs, Joannes F.M., primary, Lesterhuis, W. Joost, primary, Van Rossum, Michelle M., primary, Adema, Gosse J., primary, Figdor, Carl G., primary, Punt, Cornelis J.A., primary, and De Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 3 from Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma

Author

Aarntzen, Erik H.J.G., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Jacobs, Joannes F.M., primary, Lesterhuis, W. Joost, primary, Van Rossum, Michelle M., primary, Adema, Gosse J., primary, Figdor, Carl G., primary, Punt, Cornelis J.A., primary, and De Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Legends for Figures 1-3, Table 1 from Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination

Author

Aarntzen, Erik H.J.G., primary, De Vries, I. Jolanda M., primary, Lesterhuis, W. Joost, primary, Schuurhuis, Danita, primary, Jacobs, Joannes F.M., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Mus, Roel, primary, De Wilt, Johannes H.W., primary, Haanen, John B.A.G., primary, Schadendorf, Dirk, primary, Croockewit, Alexandra, primary, Blokx, Willeke A.M., primary, Van Rossum, Michelle M., primary, Kwok, William W., primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 2 from Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma

Author

Aarntzen, Erik H.J.G., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Jacobs, Joannes F.M., primary, Lesterhuis, W. Joost, primary, Van Rossum, Michelle M., primary, Adema, Gosse J., primary, Figdor, Carl G., primary, Punt, Cornelis J.A., primary, and De Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 3 from Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination

Author

Aarntzen, Erik H.J.G., primary, De Vries, I. Jolanda M., primary, Lesterhuis, W. Joost, primary, Schuurhuis, Danita, primary, Jacobs, Joannes F.M., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Mus, Roel, primary, De Wilt, Johannes H.W., primary, Haanen, John B.A.G., primary, Schadendorf, Dirk, primary, Croockewit, Alexandra, primary, Blokx, Willeke A.M., primary, Van Rossum, Michelle M., primary, Kwok, William W., primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure Legends 1-5 from Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma

Author

Aarntzen, Erik H.J.G., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Jacobs, Joannes F.M., primary, Lesterhuis, W. Joost, primary, Van Rossum, Michelle M., primary, Adema, Gosse J., primary, Figdor, Carl G., primary, Punt, Cornelis J.A., primary, and De Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results